NCT02489903 - RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 6, 2021

Study Completion Date

December 6, 2021

Conditions

Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine TumorsOvarian Epithelial Cancer

Interventions

DRUG

RRx-001

DRUG

Cisplatin

DRUG

Etoposide

DRUG

Carboplatin

DRUG

Irinotecan

DRUG

Vinorelbine

DRUG

Doxil

DRUG

Gemcitabine

DRUG

Taxane

DRUG

Paclitaxel

DRUG

Nab-Paclitaxel

DRUG

Pemetrexed

Trial Locations (10)

20889

Walter Reed National Military Medical Center, Bethesda

22031

Virginia Cancer Specialists, Fairfax

26506

West Virginia University, Morgantown

40503

Baptist Health, Lexington

45267

University of Cincinnati Cancer Institute, Cincinnati

46601

Memorial Hospital of South Bend, South Bend

49201

Henry Ford Allegiance Health, Jackson

63110

Washington University, St Louis

94304

Stanford University, Palo Alto

06516

VA Connecticut Cancer Center, West Haven